hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362200, orgStudyIdInfo id: LYG20230083, briefTitle: The Validation and Biological Index Studies on the Improved Social Function of ASD by 40 Hz tACS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Central South University, class: OTHER, descriptionModule briefSummary: In this proposed study, tACS will be used to intervene in the autism spectrum disorders of children and adolescents, and the efficacy of this intervention method will be evaluated, as well as the internal mechanism of adolescents' autism spectrum disorders will be discussed., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: 40 Hz tACS intervention, outcomesModule primaryOutcomes measure: Autism assessment assessment index, secondaryOutcomes measure: EEG physiological detection index, secondaryOutcomes measure: Magnetic resonance detection index, secondaryOutcomes measure: Eye movement index, secondaryOutcomes measure: Emotion recognition index, secondaryOutcomes measure: Understanding of social interaction index, secondaryOutcomes measure: Understanding of thoughts and intentions index, secondaryOutcomes measure: Social Communication Changes index, secondaryOutcomes measure: Stereotyped behavior index, secondaryOutcomes measure: Sensory index, secondaryOutcomes measure: Abnormal behavior indicator, secondaryOutcomes measure: Sleep index, otherOutcomes measure: Plasma Metabolite Levels Assessment, otherOutcomes measure: Safety evaluation SAFTEE indicator, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362187, orgStudyIdInfo id: STUDY00003238, briefTitle: VR Pilot for Pancreatitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Cedars-Sinai Medical Center, class: OTHER, descriptionModule briefSummary: The purpose of the research is to test the feasibility and preliminary impact of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) pain. The primary research procedures are questionnaires and biometric Fitbit data. The study will enroll adult patients with CP or RAP., conditionsModule conditions: Chronic Pancreatitis, conditions: Recurrent Pancreatitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, double-blind, controlled, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Gut Directed VR, interventions name: Sham Control VR, outcomesModule primaryOutcomes measure: Feasibility of home-based VR, secondaryOutcomes measure: Impact of home-based VR, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Marissa Podell, city: Los Angeles, state: California, zip: 90048, country: United States, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06362174, orgStudyIdInfo id: SHEBA-22-9902-SBH-CTIL, briefTitle: Capsule & Omics for pRedicting Exacerbation of Crohn's Disease, acronym: CORE-CD, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-02-07, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sheba Medical Center, class: OTHER_GOV, descriptionModule briefSummary: The research group have previously evaluated the benefit of serial consecutive capsule endoscopy as monitoring tool for Crohn's disease in remission, demonstrating its superior accuracy for disclosing inflammation and for prediction of flares in comparison to other diagnostic modalities such as magnetic resonance enterography and inflammatory biomarkers. Subsequently, deep learning algorithms had developed to provide excellent accuracy for identification and grading of ulcers and intestinal strictures on capsule endoscopy still images. The investigators will advance this knowledge using a parallel two-parts approach., conditionsModule conditions: Crohn's Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 62, type: ACTUAL, outcomesModule primaryOutcomes measure: Crohn's Disease Activity Index score (CDAI), primaryOutcomes measure: Disease related complications, primaryOutcomes measure: disease related hospitalization, primaryOutcomes measure: Change of crohn's disease medications, primaryOutcomes measure: opinion of the principle investigator (PI) or the treating physician, secondaryOutcomes measure: The rate of clinical flare accompanied by objective signs of mucosal inflammation., secondaryOutcomes measure: The rate of inflammatory worsening with/without accompanying clinical symptoms, eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sheba Medical Center, city: Tel-Hashomer, country: Israel, geoPoint lat: 32.04195, lon: 34.85623, hasResults: False
protocolSection identificationModule nctId: NCT06362161, orgStudyIdInfo id: IRB-300011066, briefTitle: Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-05-01, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: The purpose of this study is to help providers develop an interdisciplinary treatment pathway for functional neurological disorder (FND) at University of Alabama at Birmingham (UAB), and will involve psychiatry, speech therapy, physical therapy, and occupational therapy. The study will also help providers to evaluate the treatment pathway and publish results regarding the process and outcomes., conditionsModule conditions: Functional Neurological Disorder, conditions: Convulsion, Non-Epileptic, conditions: Functional Seizure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 1100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Patient Demographic Information, primaryOutcomes measure: Hospital Anxiety and Depression Scale (HADS), primaryOutcomes measure: ASM 121 functional assessment definitions, primaryOutcomes measure: SF-36 (subjective health and wellbeing), primaryOutcomes measure: Work and Social Adjustment Scale (WSAS), primaryOutcomes measure: Patient Health Questionnaire 15, primaryOutcomes measure: Dizziness Handicap Inventory, primaryOutcomes measure: Dizziness Symptom Profile, primaryOutcomes measure: Adult Tic Questionnaire (ATQ), primaryOutcomes measure: Child Self-Report Tic Questionnaire, primaryOutcomes measure: Parent Tic Questionnaire (PTQ), primaryOutcomes measure: Seizure Questionnaire, primaryOutcomes measure: Level 2-Somatic Symptom report, primaryOutcomes measure: Revised Children's Anxiety and Depression Scale (RCADS), primaryOutcomes measure: Functional Disability Inventory (FDI), primaryOutcomes measure: Impact on the Family Scale, primaryOutcomes measure: Pediatric Quality of Life (Peds-QL), primaryOutcomes measure: Healthcare Utility Questionnaire, primaryOutcomes measure: Assessment of control over symptoms, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 89 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Michelle Bumpers, role: CONTACT, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06362148, orgStudyIdInfo id: 1-10-72-134-23, briefTitle: Circulating Tumor DNA in Peripheral T-cell Lymphomas, acronym: CIRCULATE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2030-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University of Aarhus, class: OTHER, collaborators name: Aarhus University Hospital, descriptionModule briefSummary: The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance in a cohort of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphomas (PTCL)., conditionsModule conditions: Peripheral T-cell Lymphoma, conditions: NK/T-Cell Lymphoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, interventions name: 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), outcomesModule primaryOutcomes measure: ctDNA occurrence, primaryOutcomes measure: ctDNA quantification, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Radiographic assessment by PET/CT, secondaryOutcomes measure: Comparison of molecular and radiographic response, secondaryOutcomes measure: Spatial and temporal mutational homo- or heterogeneity, secondaryOutcomes measure: Fragment pattern analysis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Hematology, Aarhus University Hospital, status: RECRUITING, city: Aarhus, state: Central Denmark Region, zip: 8200, country: Denmark, contacts name: Patrick R Noerhave, MD, role: CONTACT, phone: +4551543715, email: panoer@rm.dk, contacts name: Francesco A d'Amore, MD, DMSc, role: CONTACT, phone: +4523708527, email: frandamo@rm.dk, contacts name: Patrick R Noerhave, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Martin B Pedersen, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Francesco A d'Amore, MD, DMSc, role: SUB_INVESTIGATOR, geoPoint lat: 56.15674, lon: 10.21076, hasResults: False
protocolSection identificationModule nctId: NCT06362122, orgStudyIdInfo id: PREDICTO-POLYP, briefTitle: Anatomo-clinico-biological Profiles in Severe Nasal Polyps, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-10-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Poitiers University Hospital, class: OTHER, descriptionModule briefSummary: Nasal sinus polyposis is a chronic inflammatory pathology of the nasal cavity and sinus cavities that causes bilateral and multifocal polyp development and has a prevalence of 2 to 4% in the general population.Therapeutic management consists of first-line medical treatment for anti-inflammatory purposes. Local corticosteroid therapy, using nasal sprays, is the background treatment. Surgical management is offered to patients in case of failure of medical treatment. Although effective, surgery does not protect patients from recurrence of symptoms related to regrowth of polyps. Recently, biologics have appeared, which despite its effectiveness, about 20% of patients have a partial or no response to these treatments. There is currently no possibility of determining the probability of response to treatments in patients.It is therefore essential to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature in order to best guide the patient's management, including the initiation of biotherapy. Indeed, patients, according to their clinical, biological characteristics and the cytokine signature of their polyps will react differently to different treatments, including surgery and biotherapy. This correlation will serve as a predictor of treatment response., conditionsModule conditions: NASAL POLYPS, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: identification anatomo-clinico-biological profiles, outcomesModule primaryOutcomes measure: Identify anatomical profiles present in nasal sinus polyposis resistant to medical treatment., primaryOutcomes measure: Evaluation of symptoms related to nasal sinus polyposis by visual analogue scale, primaryOutcomes measure: Evaluation to quality of life by Sino-Nasal Outcome Test, primaryOutcomes measure: Identify biological profiles for patients with nasal sinus polyposis, primaryOutcomes measure: Evaluation to cytokine concentration in serum for patients with nasal sinus polyposis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362109, orgStudyIdInfo id: Once tubefeeding, briefTitle: The Impact of Intermittent Nutritional Tube Supplementation in Elderly Patients With Dysphagia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Zhao Song Ling, class: OTHER_GOV, descriptionModule briefSummary: This is a prospective, randomized controlled clinical trail involved Elderly Patients With Dysphagia.The goal of this clinical trial is to compare the clinical effect of Intermittent Oro-esophageal Tube Feeding in Elderly Patients With Dysphagia. The main questions it aims to answer:Can Intermittent Nutritional Tube Supplementation help improve the nutritional status in Elderly Patients With Dysphagia.Participants will be divided into two groups randomly. All patients are given routine rehabilitation and the intervention group is given Intermittent Oro-esophageal Tube Feeding once a day., conditionsModule conditions: Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Routine rehabilitation, interventions name: Intermittent Oro-esophageal Tube Feeding, outcomesModule primaryOutcomes measure: Nutritional status-prealbumin, secondaryOutcomes measure: Nutritional status-albumin, secondaryOutcomes measure: Nutritional status-hemoglobin, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362096, orgStudyIdInfo id: pyrotinib diarrhra, briefTitle: A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Huihua Xiong, class: OTHER, descriptionModule briefSummary: To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib, conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Trastuzumab+pyrotinib+taxene, outcomesModule primaryOutcomes measure: Incidence of ≥ grade 3 diarrhea, eligibilityModule sex: ALL, minimumAge: 17 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362083, orgStudyIdInfo id: 34-317 ex 21/22, briefTitle: Urethral Stricture Database, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2034-01-15, completionDateStruct date: 2034-03-15, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Medical University of Graz, class: OTHER, descriptionModule briefSummary: Establishment of a clinical urethral stricture database for a prospective longitudinal cohort study., conditionsModule conditions: Urethral Stricture, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaires and data collection, outcomesModule primaryOutcomes measure: Success rate of urethral reconstructive surgeries, secondaryOutcomes measure: Complications of urethral reconstructive surgeries, secondaryOutcomes measure: Sexual function after urethral reconstructive surgeries, secondaryOutcomes measure: Health status after urethral reconstructive surgeries, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Röthl Martina Anna, status: RECRUITING, city: Graz, state: Styria, zip: 8036, country: Austria, contacts name: Marianne Leitsmann, Prof. Dr., role: CONTACT, phone: +43 316 385 80550, email: martina.roethl@medunigraz.at, contacts name: Marianne Leitsmann, Prof. Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.06667, lon: 15.45, hasResults: False
protocolSection identificationModule nctId: NCT06362057, orgStudyIdInfo id: ADMNF-0020324, briefTitle: Biomechanical Effects of Digitally Constructed Subperiosteal Implants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2024-06-20, completionDateStruct date: 2024-07-27, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Menoufia University, class: OTHER, descriptionModule briefSummary: Subperiosteal implants were first introduced in 1940 and then used worldwide for the treatment of edentulous maxilla or mandible with advanced bone atrophy., conditionsModule conditions: Bone Loss, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: Subperiosteal implant framework, outcomesModule primaryOutcomes measure: bone loss under the implants, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mohammed A. El-Sawy, status: RECRUITING, city: Mansoura, zip: 12345, country: Egypt, contacts name: Mohammed A. El-Sawy, PhD, role: CONTACT, phone: 161314522, email: Dr_sawy@windowslive.com, contacts name: PhD, role: CONTACT, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06362044, orgStudyIdInfo id: P24-120, briefTitle: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-07, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: AbbVie, class: INDUSTRY, descriptionModule briefSummary: Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan.Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan.Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months.There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice., conditionsModule conditions: Chronic Lymphocytic Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 89, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Percentage of Participants with Undetectable Minimal Residual Disease (uMRD), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center Hospital East /ID# 265970, status: RECRUITING, city: Kashiwa, state: Chiba, zip: 277-8577, country: Japan, geoPoint lat: 35.86224, lon: 139.97732, hasResults: False